Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $7.72 Million - $10.2 Million
-191,800 Reduced 17.7%
891,800 $37 Million
Q1 2024

May 09, 2024

BUY
$47.98 - $54.4 $52 Million - $58.9 Million
1,083,600 New
1,083,600 $58.8 Million
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $26.2 Million - $31.4 Million
-426,200 Reduced 49.45%
435,700 $31.8 Million
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $26.9 Million - $31.4 Million
502,200 Added 139.62%
861,900 $53.7 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $16.2 Million - $17.6 Million
-260,900 Reduced 42.04%
359,700 $24 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $12 Million - $13.3 Million
209,200 Added 50.85%
620,600 $37.4 Million
Q1 2020

May 13, 2020

BUY
$46.4 - $67.43 $8.47 Million - $12.3 Million
182,600 Added 79.81%
411,400 $22.9 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $31.1 Million - $40.6 Million
-631,900 Reduced 73.42%
228,800 $14.7 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $20.2 Million - $24 Million
472,800 Added 121.89%
860,700 $43.6 Million
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $16.2 Million - $17.9 Million
363,800 Added 1509.54%
387,900 $17.6 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $9.07 Million - $10.8 Million
-201,000 Reduced 89.29%
24,100 $1.15 Million
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $1.42 Million - $1.84 Million
29,100 Added 14.85%
225,100 $11.7 Million
Q3 2018

Nov 09, 2018

BUY
$55.19 - $62.25 $2.27 Million - $2.56 Million
41,200 Added 26.61%
196,000 $12.2 Million
Q2 2018

Aug 08, 2018

BUY
$50.53 - $62.98 $2.69 Million - $3.36 Million
53,300 Added 52.51%
154,800 $8.57 Million
Q1 2018

May 09, 2018

BUY
$59.92 - $68.98 $6.08 Million - $7 Million
101,500 New
101,500 $6.42 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.